Table 4.

Disease course of multifocal placebo patients by symptoms and by signs after the CIS

	All multifocal	Multifocal by symptoms	Multifocal by signs	p-value*
N	83	50 (60%)	33 (40%)
CDMS %* over 2 years	44%	49%	37%	0.3554†
Median annualized cumulative number of NALs over the study (quartiles)	3.6 (1.0–12.5)	5.3 (1.6–13.4)	2.6 (0–7.0)	0.0424‡

*Compares multifocal patients by symptoms vs. multifocal patients by signs

^†Kaplan-Meier estimate at day 720, Log rank test

^‡Wilcoxon test

CDMS: clinically definite MS

NAL: newly active lesion

Gd: gadolinium